Elevance Health, Inc. (ELV) recently reported its Q2 2025 results, posting adjusted EPS of $8.84, slightly missing expectations. The company saw a $49.4 billion revenue, up 14% YoY, but declines in Medicaid and ACA enrollment affected membership. Looking forward, ELV reduced its full-year EPS guidance to $30 due to cost pressures but remains focused on stabilizing margins. Mizuho maintained a ‘Buy’ rating on ELV with a $342 price target, citing growth potential in Carelon and strong execution in Medicare Advantage. ELV offers integrated medical, pharmacy, and care delivery solutions and is listed as a cheap value stock to buy.

Read more at Yahoo Finance: Elevance Health, Inc. (ELV) Reports Q2 2025 Results; Mizuho Maintains ‘Buy’ Rating With $342 PT